Loading...
Pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC with PD-L1 tumor proportion score >= 50%: KEYNOTE-598 3-year follow-up
Abreu, D. R. Reck, M. Sendur, N. Park, K. Lee, D. H. Cicin, I. Yumuk, P. F. Orlandi, F. J. Leal, T. A. Soparattanapaisarn, N.
Abreu, D. R.
Reck, M.
Sendur, N.
Park, K.
Lee, D. H.
Cicin, I.
Yumuk, P. F.
Orlandi, F. J.
Leal, T. A.
Soparattanapaisarn, N.
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2022
Publisher
Collections
Files
Keywords
Type
Meetings and Proceedings
Citation
Abreu DR, Reck M, Sendur N, Park K, Lee DH, Cicin I, et al. Pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC with PD-L1 tumor proportion score >= 50%: KEYNOTE-598 3-year follow-up. Annals of Oncology. 2022;33:S30-S1.